LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
+4.47%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$279M
AUM Growth
+$279M
(+4.7%)
Cap. Flow
+$53.5M
Cap. Flow
% of AUM
19.18%
Top 10 Holdings %
Top 10 Hldgs %
98.16%
Holding
20
New
2
Increased
5
Reduced
2
Closed
6
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$35.4M |
| 2 |
GH Research
GHRS
|
$17.5M |
| 3 |
Cullinan Oncology
CGEM
|
$14.8M |
| 4 |
Stoke Therapeutics
STOK
|
$697K |
| 5 |
C4 Therapeutics
CCCC
|
$393K |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$8.61M |
| 2 |
ALLK
Allakos
ALLK
|
$4.39M |
| 3 |
Caribou Biosciences
CRBU
|
$1.08M |
| 4 |
Vor Biopharma
VOR
|
$707K |
| 5 |
Merus
MRUS
|
$505K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GH Research
GHRS
$837M
| $71.1M | 25.45% |
6,443,940
+1,584,946
| +33% | +$17.5M |
|
|
2
Merus
MRUS
$5.01B
| $66M | 23.65% |
1,568,841
-12,000
| -0.8% | -$505K |
|
|
3
Protagonist Therapeutics
PTGX
$3.67B
| $35.4M | 12.69% |
+733,014
| New | +$35.4M |
|
|
4
Stoke Therapeutics
STOK
$1.07B
| $35.2M | 12.6% |
5,291,929
+104,738
| +2% | +$697K |
|
|
5
Cullinan Oncology
CGEM
$445M
| $24.3M | 8.72% |
3,215,722
+1,957,927
| +156% | +$14.8M |
|
6
Allogene Therapeutics
ALLO
$249M
| $16.1M | 5.78% |
11,057,009
+182,286
| +2% | +$266K |
|
|
7
C4 Therapeutics
CCCC
$185M
| $11.4M | 4.07% |
7,098,133
+245,389
| +4% | +$393K |
|
8
TScan Therapeutics
TCRX
$102M
| $7.39M | 2.65% |
5,357,347
| – | – |
|
9
Precision BioSciences
DTIL
$57.8M
| $3.65M | 1.31% |
766,051
| – | – |
|
10
iBio
IBIO
$15.9M
| $3.47M | 1.24% |
862,279
| – | – |
|
11
Passage Bio
PASG
$22.7M
| $3.27M | 1.17% |
9,256,953
| – | – |
|
|
UPB
12
Upstream Bio, Inc. Common Stock
UPB
$1.09B
| $1.34M | 0.48% |
219,247
-20,795
| -9% | -$127K |
|
|
NEUP
13
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $264K | 0.09% |
45,806
| – | – |
|
14
Design Therapeutics
DSGN
$315M
| $255K | 0.09% |
+65,954
| New | +$255K |
|
|
ALLK
15
DELISTED
Allakos
ALLK
| – | – |
-3,628,144
| Closed | -$4.39M |
|
|
CNTA
16
Centessa Pharmaceuticals
CNTA
$2.32B
| – | – |
-17,400
| Closed | -$291K |
|
|
17
Caribou Biosciences
CRBU
$174M
| – | – |
-680,189
| Closed | -$1.08M |
|
|
18
Keros Therapeutics
KROS
$618M
| – | – |
-544,001
| Closed | -$8.61M |
|
19
Repare Therapeutics
RPTX
$73M
| – | – |
-79,176
| Closed | -$104K |
|
|
20
Vor Biopharma
VOR
$258M
| – | – |
-637,218
| Closed | -$707K |
|